Tag: krystexxa

Krystexxa comes before the FDA Arthritis Advisory Committee Meeting on Tuesday 16th June. This is the latest stage to try and get approval for the second new gout drug this year. Hot on the heals of Uloric, the US brandname for febuxostat, pegloticase (formerly known as PEG-uricase) seeks release under Savient's brand new name of Krystexxa. FDA review has been postponed from February to give time for additional analysis of cardiovascular risks. So what does this mean for gout sufferers? Assuming approval is given, do not be thinking that you have a newer, easier option for controlling your uric acid. Krystexxa cannot be taken orally. You get dosed up every two weeks with 8mg delivered by intravenous injection. As well as being inconvenient, there are fairly high documented reaction rates. On a positive side, it is good that severe gout sufferers have an alternative if they cannot tolerate allopurinol. So expect plenty drug company stimulated hype over the next few weeks. It is such a pity that similar...

I keep getting asked "Where can I get pegloticase" The answer, "Nowhere yet," is probably not what you want to hear, but read on for the latest news. Pegloticase is a generic name for PEG-uricase - a genetically engineered form of uricase. Uricase is an enzyme present in some animals that breaks down uric acid in the body. Humans do not produce uricase, so techniques have been developed to produce a type of uricase that humans can use. Various versions of this treatment are being developed. The one that is most advanced is expected to be approved soon under the brand name Krystexxa, in the USA. This was recommended for approval in June this year, and the FDA are expected to give final approval on August 1st. So does this mean you can rush out and buy some in August? Absolutely not. Even when production gets up to speed, this is not a gout medication for self-administration. You need to go to your doctor, a clinic, or...